Welcome to our dedicated page for OptiNose news (Ticker: $OPTN), a resource for investors and traders seeking the latest updates and insights on OptiNose stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OptiNose's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OptiNose's position in the market.
Optinose (NASDAQ: OPTN), a pharmaceutical company specializing in treatments for ENT and allergy patients, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ.
The presentation, scheduled for May 20, 2024, at 11:30 a.m. ET, will feature a company overview and business update from Optinose's management team.
The live presentation will be webcast, and a replay will be available for 30 days on the Optinose website.
Optinose (NASDAQ:OPTN) reported Q1 2024 net revenue of $14.9 million for XHANCE, marking a 26% increase from Q1 2023. The company forecasts full-year 2024 XHANCE net revenues between $85-$95 million, with peak revenue expectations of at least $300 million. Optinose anticipates positive GAAP income for 2025. In March 2024, the FDA approved XHANCE for chronic rhinosinusitis without nasal polyps, significantly expanding its market. The approval of a second manufacturing site and a $55 million direct offering were also highlighted. Despite these advancements, Q1 2024 saw a net loss of $14.1 million, and operating expenses are projected between $95-$101 million for 2024.
Optinose, a pharmaceutical company specializing in ENT and allergy treatments, will announce its first quarter 2024 financial results on May 14, 2024. The company will host a conference call to discuss the results and corporate updates.
Optinose, a pharmaceutical company specializing in ENT and allergy treatments, announced a $55 million registered direct offering. The offering, led by Nantahala Capital and The D. E. Shaw Group, aims to fund operations through 2025. With a post-offering cash balance of approximately $100 million, the company expects XHANCE net revenues to range between $85 to $95 million for the full year 2024.